Featured Studies Results
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
https://www.facingourrisk.org/research-clinical-trials/study/101 /a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/342 /heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer
Clinicaltrials.gov identifier:
NCT06748222 (https://clinicaltrials.gov/show/NCT06748222)
Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression
Clinical and Molecular Studies of Li-Fraumeni Syndrome and TP53-Associated Disorders
https://www.facingourrisk.org/research-clinical-trials/study/340 /clinical-and-molecular-studies-of-li-fraumeni-syndrome-and-tp53-associated-disorders
Clinicaltrials.gov identifier:
NCT04367246 (https://clinicaltrials.gov/show/NCT04367246)
Surveys, Registries, Interviews
Study for Li-Fraumeni Syndrome patients, family and household members
Using the Drug eRapa to Prevent the Growth of Polyps in People with Familial Adenomatous Polyposis (SERENTA)
https://www.facingourrisk.org/research-clinical-trials/study/348 /study-of-the-drug-erapa-in-people-with-familial-adenomatous-polyposis-serenta
Clinicaltrials.gov identifier:
NCT06950385 (https://clinicaltrials.gov/show/NCT06950385)
Prevention
Prevention study for people with Familial Adenomatous Polyposis (FAP) who have polyps in the colon or rectum
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345 /treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer
Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)
Treatment
Biomarker study for people with early-stage breast cancer
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
https://www.facingourrisk.org/research-clinical-trials/study/149 /promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness
Clinicaltrials.gov identifier:
NCT04995198 (https://clinicaltrials.gov/show/NCT04995198)
Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer
Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/343 /a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT05929768 (https://clinicaltrials.gov/show/NCT05929768)
Treatment
Treatment study for early-stage triple-negative breast cancer
Pancreatic Cancer Screening Study (CAPS5)
https://www.facingourrisk.org/research-clinical-trials/study/222 /pancreatic-cancer-screening-studycaps5
Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)
Prevention
Screening study for people at high risk for pancreatic cancer
Registry for People at Increased Risk for Pancreatic Cancer
https://www.facingourrisk.org/research-clinical-trials/study/331 /registry-for-people-at-increased-risk-for-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT06151223 (https://clinicaltrials.gov/show/NCT06151223)
Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer
Study of the Drug Olvi-Vec in Women with Ovarian Cancer
https://www.facingourrisk.org/research-clinical-trials/study/334 /study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer
Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)
Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy
Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)
https://www.facingourrisk.org/research-clinical-trials/study/288 /testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap
Clinicaltrials.gov identifier:
NCT05552755 (https://clinicaltrials.gov/show/NCT05552755)
Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery
The American Cancer Society’s “VOICES of Black Women” Observational Study
https://www.facingourrisk.org/research-clinical-trials/study/336 /the-american-cancer-societys-voices-of-black-women-observational-study
Surveys, Registries, Interviews
Survey for Black women who have never been diagnosed with cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304 /olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer
https://www.facingourrisk.org/research-clinical-trials/study/335 /understanding-the-emotional-and-social-experiences-of-individuals-living-with-ovarian-cancer
Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer
CHANCES: Studying the Connection Between Chemotherapy Exposure and Secondary Cancers of the Blood in Ovarian and other Cancer Survivors
https://www.facingourrisk.org/research-clinical-trials/study/325 /chances-studying-the-connection-between-chemotherapy-exposure-and-secondary-cancers-of-the-blood-in-ovarian-cancer-survivors
Clinicaltrials.gov identifier:
NCT06295965 (https://clinicaltrials.gov/show/NCT06295965)
Surveys, Registries, Interviews
Registry for people who completed treatment for ovarian cancer
PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
https://www.facingourrisk.org/research-clinical-trials/study/291 /patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease
Clinicaltrials.gov identifier:
NCT04472338 (https://clinicaltrials.gov/show/NCT04472338)
Prevention
Screening study for people with a mutation linked to prostate cancer risk
Social Support and Coping Strategies Among LGBTQIA+ Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/303 /social-support-and-coping-strategies-among-lgbtqia-cancer-patients
Surveys, Registries, Interviews
Survey for LGBTQIA+ cancer patients who reside in the United States
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.